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Ischemia augments alloimmune 
injury through IL-6-driven CD4+ 
alloreactivity
Mayuko Uehara1, Zhabiz Solhjou1, Naima Banouni1, Vivek Kasinath1, Ye Xiaqun1, Li Dai1, 
Osman Yilmam1, Mine Yilmaz1, Takaharu Ichimura2, Paolo Fiorina3, Paulo N. Martins4, 
Shunsuke Ohori1, Indira Guleria1, Omar H. Maarouf1, Stefan G. Tullius5, Martina M. McGrath1 
& Reza Abdi1
Ischemia reperfusion injuries (IRI) are unavoidable in solid organ transplantation. IRI augments 
alloimmunity but the mechanisms involved are poorly understood. Herein, we examined the effect of 
IRI on antigen specific alloimmunity. We demonstrate that ischemia promotes alloimmune activation, 
leading to more severe histological features of rejection, and increased CD4+ and CD8+ T cell graft 
infiltration, with a predominantly CD8+ IFNγ+ infiltrate. This process is dependent on the presence 
of alloreactive CD4+ T cells, where depletion prevented infiltration of ischemic grafts by CD8+ IFNγ+ 
T cells. IL-6 is a known driver of ischemia-induced rejection. Herein, depletion of donor antigen-
presenting cells reduced ischemia-induced CD8+ IFNγ+ allograft infiltration, and improved allograft 
outcomes. Following prolonged ischemia, accelerated rejection was observed despite treatment with 
CTLA4Ig, indicating that T cell costimulatory blockade failed to overcome the immune activating 
effect of IRI. However, despite severe ischemic injury, treatment with anti-IL-6 and CTLA4Ig blocked 
IRI-induced alloimmune injury and markedly improved allograft survival. We describe a novel pathway 
where IRI activates innate immunity, leading to upregulation of antigen specific alloimmunity, resulting 
in chronic allograft injury. Based on these findings, we describe a clinically relevant treatment strategy 
to overcome the deleterious effect of IRI, and provide superior long-term allograft outcomes.
Ischemia reperfusion injury (IRI) is an inevitable consequence of transplantation. IRI leads to a cascade of 
intra-graft inflammation, and initiates immune activation within the transplanted organ1. Controlling innate 
immunity early on post-transplantation is a key component of innovative strategies to promote allograft accept-
ance2,3. Furthermore, critical organ shortages have necessitated the increased use of organs from donors of older 
age or with co-morbid diseases for transplantation4–6. Owing to pre-existing damage, these organs have shorter 
expected duration of function and more readily accumulate ischemic injuries, which can further compromise 
their long-term outcomes7–13. Therefore, an improved understanding of the link between IRI and increased allo-
graft immunogenicity has highly practical applications for the field of transplantation.
Antigen presenting cells (APC) within the allograft are activated by danger signals released during IRI14,15. 
In particular, allograft-resident dendritic cells (DC) are perfectly poised to regulate the interplay between innate 
and antigen-specific alloimmunity16–19. We have previously shown that allograft-resident DCs increase IL-6 pro-
duction in the setting of ischemia, and blockade of IL-6 improves allograft outcomes18. IL-6 plays a key role in 
alloimmune injury both by directly increasing alloimmune responses and indirectly, by augmenting inflamma-
tion and innate immunity, which also promote graft rejection20–23. However, the effector mechanism linking IL-6, 
allospecific T cell activation and chronic rejection has not been identified.
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Here, we used both a typical Class I MHC mismatch model, and an antigen-specific TCR transgenic model of 
cardiac transplantation to comprehensively examine the impact of IRI on antigen-specific alloreactive CD4+ and 
CD8+ T cells. OTI transgenic mice express a transgenic CD8+ T cell receptor, and OTII transgenic mice express a 
transgenic CD4+ T cell receptor, both of which are reactive to OVA. Transgenic mice expressing OVA on all cells 
were used as donors in our studies24,25. Using the OVA/OT system, we transplanted ischemic and control OVA 
hearts into OTI and OTII recipients, and studied the subsequent activation of alloreactive CD4+ T cells.
In this study, we observed that IRI is associated with accelerated allograft rejection, characterized by allograft 
infiltration with CD8+ IFNγ+ T cells. We identified allospecific CD4+ T cells as critical mediators of enhanced 
alloimmune reactivity following IRI. However, despite their central role, costimulatory blockade of CD4+ T cells 
with CTLA4Ig failed to overcome the negative effect of prolonged ischemia on allograft survival. Addition of 
anti-IL-6 therapy to CTLA4Ig overcame the effect of severe allograft ischemia, leading to long-term graft survival 
in a full MHC mismatch model. This approach represents a clinically applicable treatment model to reduce early 
immune activation by IRI and improve long-term allograft outcomes.
Results
Ischemia augments alloimmunity. BALB/c hearts were harvested and transplanted into fully MHC mis-
matched C57BL/6 recipients within 30 minutes (control group) or after storage at 4 degrees Celsius, immersed 
in University of Wisconsin (UW) solution, for 8 hours (ischemic group). Recipients were followed for transplant 
survival. We observed no change in graft survival between groups (MST: 7 vs.7 days, n = 6–7 mice/group, p = 0.3) 
(Fig. 1A). However, ischemic grafts harvested at day 6 post-transplant showed increased cellular infiltration with 
CD4+ and CD8+ T cells compared to control, as assessed by histological analysis (Fig. 1B). Graft infiltrating cells 
were isolated on day 6 post-transplant from control and ischemic grafts and analyzed by flow cytometry. Absolute 
cell numbers were enumerated and were significantly higher for both CD4+ and CD8+ T cells in ischemic vs. con-
trol grafts. (12.6 × 103 ± 1.2 × 103 vs. 7.5 × 103 ± 1 × 103, *p < 0.05 for CD4+ T cells and 38.5 × 103 ± 1.4 × 103 vs. 
24 × 103 ± 4.8 × 103, *p < 0.05 for CD8+ T cells, respectively, n = 3/group) (Fig. 1C). Furthermore, the percentage 
of IFNγ producing CD8+ T cells was significantly higher in ischemic grafts compared to controls (7.0 ± 0.5% vs. 
3.7 ± 0.2%, *p < 0.05, respectively, n = 3/group) (Fig. 1D).
Allospecific CD8+ T cells lead to prompt rejection, which is not augmented by IRI. The relative 
importance of antigen specific CD4+ and CD8+ T cells in alloimmune responses induced by IRI is unknown. 
Given the predominance of CD8+ IFNγ+ T cells in rejecting ischemic allografts in the full MHC mismatch 
model, we initially focused on antigen specific CD8+ T cells. To assess this, we transplanted control and ischemic 
hearts from OVA donors into CD8+ TCR transgenic OTI recipients. Grafts in both groups were rapidly rejected 
with no difference in survival between ischemic and control hearts (MST: 3 vs. 3 days, p = 0.51, n = 5/group) 
(Supplementary Figure 1A). Both groups showed similar severity of cellular infiltration and tissue necrosis (4 
days post-transplant) suggesting that in a strongly alloreactive CD8+-driven model of rejection, IRI does not 
augment the CD8+ response (Supplementary Figure 1B).
CD4+ alloreactive T cells play a critical role in augmenting alloimmune responses by IRI. To 
examine the role of antigen specific CD4+ T cells in allograft rejection augmented by IRI, control and ischemic 
OVA hearts were transplanted into CD4+ TCR transgenic OTII hosts. Ischemic grafts underwent accelerated allo-
graft rejection as compared to control (MST: 52.5 vs. 89.5 days, **p < 0.01, n = 4/group) (Fig. 2A). Histologically, 
ischemic grafts showed greater tissue destruction and more severe infiltration by CD4+ and CD8+ T cells at day 
6 post-transplant (Fig. 2B). To quantify infiltrating T cells, graft-infiltrating lymphocytes were isolated at day 6 
post-transplant and analyzed by flow cytometry. The absolute numbers of CD4+ T cells were 7.3 × 104 ± 2.9 × 104 
vs. 23.9 × 104 ± 4.2 × 104 and CD8+ T cells were 1.9 × 104 ± 0.4 × 104 vs. 3.4 × 104 ± 0.2 × 104 in control and 
ischemic groups, respectively (*p < 0.05, n = 3/group) (Fig. 2C).
CD8+ IFNγ+ T cells are the predominant intra-graft lymphocyte population in ischemia induced 
alloreactivity. To assess the intra-graft immune response, we next characterized graft infiltrating T cell pop-
ulations in OT II recipients of OVA hearts. Control and ischemic grafts were harvested at day 6 post-transplant; 
graft-infiltrating lymphocytes were isolated and analyzed by intracellular cytokine staining and flow cytom-
etry. Ischemic allografts had similar numbers of Foxp3+ regulatory T cells (absolute cell count: 6498 ± 844.7 
vs. 5364 ± 2925.1, p = 0.6, n = 3/group), but significantly greater numbers of CD4+ IL17+ (absolute cell count: 
2615 ± 461.5 vs. 816.1 ± 328.9, *p < 0.05, n = 3/group) and CD4+ IFNγ+ (absolute cell count: 8518 ± 1503 vs. 
2206 ± 888.8, *p < 0.05, n = 3/group) than control grafts (Supplementary Figure 2A,B and C, respectively), indi-
cating that IRI promotes pro-inflammatory allospecific CD4+ T cell infiltration in this heart transplant model. 
Similar to the full mismatch transplant model, we observed a marked increase in IFNγ producing CD8+ T cells 
at 6 days post-transplant in ischemic grafts as compared to controls (27.77 ± 2.46% vs. 13.04 ± 3.04%, *p < 0.05, 
respectively, n = 3/group) (Fig. 2D), suggesting that in the setting of IRI, CD4+ alloreactive T cells mediate allo-
immune injury via IFNγ producing CD8+ T cells.
Finally, to assess peripheral alloimmune responses, spleen and draining lymph nodes (DLN) of OT II recipi-
ents of control or ischemic OVA hearts were harvested at day 6 post-transplant and analyzed by flow cytometry. 
No differences were seen in the frequency of CD4+ Foxp3+ regulatory T cells (Tregs), CD4+ IL17+ and CD8+ 
IFNγ+ producing T cells in the spleen or graft DLN (Supplementary Figure 3A and B for spleen and DLN, respec-
tively). However, recipients of ischemic heart grafts showed greater allospecific IFNγ production by splenocytes 
as assessed by ELISPOT analysis (68.17 ± 3.32 vs. 25.63 ± 3.45 spots/106 cells, ***p < 0.001, respectively, n = 3/
group) (Supplementary Figure 4Α). These findings indicate that accelerated alloimmune injury induced by IRI in 
the early post-transplant period is driven largely by local, intra-graft alloimmune activation in this model.
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Depletion of CD4+ alloreactive T cells abrogates augmentation of intra-graft IFNγ producing 
CD8+ T cells. To further examine the importance of allospecific CD4+ T cells in IRI induced alloimmunity, 
we depleted CD4+ T cells from OTII recipients using anti-CD4 antibody, administered on day −3 to −1 prior 
to transplantation. Depletion was confirmed by peripheral blood flow cytometry. Following CD4+ depletion, 
OVA control and ischemic heart allografts were transplanted into OTII recipients. Histological analysis of grafts 
harvested at day 6 revealed healthy myocytes without evidence of inflammation in either control or ischemic 
allografts. Immunohistochemical staining and lymphocyte enumeration by flow cytometry showed a marked 
Figure 1. Ischemia is associated with increased graft infiltration and augmentation of the alloimmune response 
in a complete allo-mismatch model. Full MHC mismatch BALB/c hearts were harvested and transplanted into 
C57BL/6 recipients within 30 minutes (control group) or after 8 hours stored in UW solution, at 4 °C (ischemic 
group). Recipients were followed for transplant survival or grafts were harvested at day 6. (A) No difference 
was observed in tempo of graft rejection between control and ischemic group (MST: 7 vs. 7 days, p = 0.3, 
n = 6–7/group) (B) Histological analysis at 6 days post-transplant showed increased tissue injury and increased 
CD4+ and CD8+ T cell infiltration of ischemic heart grafts as compared to controls. (Scale bar 100 μm for 
H&E stain, 50 μm for CD4 and CD8 stain). (C) Enumeration of absolute number of cardiac graft-infiltrating 
cells, as assessed by flow cytometry of control and ischemic grafts, revealed a greater number of CD4+ and 
CD8+ infiltrating ischemic grafts (7.5 × 103 ± 1 × 103 vs. 12.6 × 103 ± 1.2 × 103, *p < 0.05 for CD4+ T cells and 
24 × 103 ± 4.8 × 103 vs. 38.5 × 103 ± 1.4 × 103, *p < 0.05 for CD8+ T cells, respectively, n = 3/group). (D) A 
marked increase in the frequency of IFNγ-producing CD8+ T cell in ischemic grafts as compared to controls 
(7.0 ± 0.5% vs. 3.7 ± 0.2%, *p < 0.05, respectively, n = 3/group). Representative flow plots, gating on CD8+ T 
cells.
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reduction in the number of CD8+ T cells in both control and ischemic heart grafts at day 6 post-transplant 
(657 ± 322 vs. 1069 ± 478, p = 0.5, respectively) (Fig. 3A and B). Graft-infiltrating CD8+ IFNγ+ T cells were also 
rare in both control and ischemic grafts following CD4+ depletion (Fig. 3C) (compare to Fig. 2D). ELISPOT 
analysis of splenocytes harvested on day 6 showed that CD4+ T cell depletion led to a marked reduction in the 
frequency of allospecific IFNγ producing splenocytes in both groups, with no difference observed between recipi-
ents of control and ischemic heart grafts (2.4 ± 0.5 vs. 9.3 ± 3.7 spots/106 cells, p = 0.13, respectively, n = 3/group). 
(Supplementary Figure 4B).
Graft resident APC promote alloreactive CD4+ T cells infiltration following IRI. Cardiac anti-
gen presenting cells (APC) comprise a mixed population of DCs, macrophages and monocytes26–28 and act as 
a critical link between innate and adaptive alloimmune responses. We have previously reported that ischemia 
promotes autophagy and increased IL-6 production by ischemic allograft resident DCs18. To examine the role of 
graft-resident APC in promoting CD8+ IFNγ+ T cell infiltration following IRI, we depleted donor cardiac APC by 
administration of liposomal clodronate to the donor prior to transplantation, as previously described29. Following 
clodronate treatment, we saw significant depletion of CD11c+ DCs in heart grafts, as assessed by flow cytometry 
Figure 2. Ischemia promotes accelerated rejection in a CD4+ allospecific model of transplantation and 
is associated with increased graft-infiltrating CD8+ IFNγ producing T cells. Control and ischemic OVA 
hearts were transplanted into OTII recipients. (A) Ischemic OVA heart grafts showed accelerated rejection 
as compared to controls (MST: 52.5 vs. 89.5 days, **p < 0.01, n = 4/group). (B) Histology of ischemic OVA 
heart grafts showed an increase in tissue necrosis, inflammatory cell infiltrates and an increase in intra-graft 
CD4+ and CD8+ T cells on day 6 post-transplant compared to controls. (Scale bar 100 μm for H&E, CD4 
and CD8 stain. Inset scale bar 30 μm). (C) Quantification of graft-infiltrating CD4+ and CD8+ T cells by flow 
cytometry shows a significantly greater number of CD4+ and CD8+ T cells in ischemic grafts compared to 
control (23.9 × 104 ± 4.2 × 104 vs 7.3 × 104 ± 2.9 × 104, *p < 0.05 for CD4+ T cells and 3.4 × 104 ± 0.2 × 104 vs 
1.9 × 104 ± 0.4 × 104, *p < 0.05 for CD8+ T cells, respectively, n = 3/group). (D) A significantly greater number 
and percentage of IFNγ-producing CD8+ T cells in ischemic grafts as compared to controls, (27.77 ± 2.46% vs. 
13.04 ± 3.04%, *p < 0.05, n = 3/group). Representative flow plots, gated on CD8+ T cells.
www.nature.com/scientificreports/
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at the time of transplantation (control vs. clodronate treatment; 109.9 × 103 ± 13.0 × 103 vs. 29.2 × 103 ± 8.4 × 103, 
**p < 0.01) (Supplementary Figure 5A). A non-significant decrease in intra-graft F4/80+ macrophages was also 
observed. (control vs. clodronate treatment; 545.1 × 103 ± 223.5 × 103 vs. 318.1 × 103 ± 74.7 × 103, p = 0.39) 
(Supplementary Figure 5B).
APC-depleted control and ischemic OVA grafts were harvested on day 6 post-transplant. Both groups showed 
a similar degree of cellular infiltration and tissue injury with very few graft-infiltrating CD4+ and CD8+ T cells 
observed by histological analysis (Fig. 4A). Similarly, no differences were seen in CD8+ IFNγ+ T cell allograft 
infiltration of control versus ischemic grafts (0.09 ± 0.03% vs. 0.12 ± 0.02%, control vs. ischemia, p = 0.46) 
(Fig. 4B). Of note, APC depletion led to a highly significant reduction in frequency of CD8+ IFNγ+ T cells in 
ischemic grafts as compared to non-depleted ischemic grafts (compare to Fig. 2D) (0.12 ± 0.02% vs. 27.7 ± 2.46%, 
***p < 0.001). These data indicate that depletion of donor intra-graft APC prior to transplantation abrogated the 
enhanced alloreactive T cell infiltration observed after IRI.
Early production of IL-6 by APC as a mechanism to promote alloreactive CD4+ T cell infiltration 
following IRI. We have previously shown that ischemic DCs produce a large amount of IL-6 in vitro, a key 
inflammatory cytokine potentiating the activity of alloreactive T cells18,30,31. We next sought to assess its role in 
the augmented alloimmune response observed after IRI. Control and ischemic OVA hearts were transplanted into 
OTII recipients and mRNA was extracted from hearts harvested on day 1, 3, and 6 post-transplant. Comparing 
ischemic with control grafts, we found that the relative expression of IL-6 in ischemic heart allografts was signif-
icantly elevated. It peaked at day 1 post-transplant (*p < 0.05, n = 4/group), and remained significantly elevated 
up to day 3 (*p < 0.05, n = 3/group) (Supplementary Figure 6A).
To investigate the source of this early increase in IL-6, control and ischemic OVA heart grafts were harvested 
at day 1 post-transplant into OTII recipients. At this early time point, very few graft infiltrating CD4+ or CD8+ T 
cells were present (Supplementary Figure 6B). We therefore hypothesized that ischemic APC, including allograft 
resident DCs, are the major source of IL-6 in the graft early post-transplant. Indeed, ischemic and control allo-
grafts harvested from clodronate-treated donors had a significant reduction of IL-6 expression, with undetectable 
IL-6 levels at day 1 post-transplant in both groups after APC depletion (n = 3/group) (Supplementary Figure 6C).
Antagonizing IL-6 markedly reduces allograft infiltration by T cells following IRI. To test the 
functional importance of IL-6 in IRI induced alloimmunity, OTII recipients of control and ischemic OVA hearts 
were treated with anti-IL-6 0.1 mg by intraperitoneal injection on days 0 to 3 and on day 5 post-transplant. On day 
6 post-transplant, grafts were harvested and analyzed for infiltrating T cells.
Figure 3. Depletion of CD4+ alloreactive T cells abrogates IRI-induced augmentation of intra-graft IFNγ-
producing CD8+ T cells. OTII recipients were treated with anti-CD4 antibody prior to receiving control or 
ischemic OVA hearts. Grafts were harvested at day 6 post-transplant for analysis. (A) No differences in allograft 
infiltration or evidence of rejection seen in either group following CD4 depletion. No intra-graft CD4+ T cells 
were detected and rare CD8+ T cells were detected by histological analysis, with no notable difference between 
control and ischemic organs. (Scale bar 100 μm for H&E, CD4 and CD8 stain. Inset scale bar 30 μm). (B) There 
was no statistical difference between absolute number of CD8+ T cells infiltrating control and ischemic grafts as 
enumerated by flow cytometry (657 ± 322 vs. 1069 ± 478, p = 0.5, n = 3/group). (C) No IFNγ-producing CD8+ 
T cells were detected in the grafts after CD4+ depletion (n = 3/group).
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IL-6 blockade prevented IRI-induced allograft infiltration, with an overall reduction in intra-graft CD4+ 
and CD8+ T cells, (Fig. 5A). Following anti-IL-6, no differences were observed in the number of T cells in 
control versus ischemic grafts (15.4 × 104 ± 1.4 × 104 vs. 18.5 × 104 ± 0.1 × 104, p = 0.1 for CD4+ T cells and 
1.1 × 104 ± 0.1 × 104 vs. 1.4 × 104 ± 0.1 × 104, p = 0.29 for CD8+ T cells, respectively, n = 3/group) as assessed 
by flow cytometry of graft-infiltrating leukocytes (Fig. 5B). Furthermore, treatment with anti-IL-6 signif-
icantly decreased CD4+ and CD8+ T cell infiltration of ischemic grafts (anti-IL-6 treated ischemic grafts vs. 
Figure 4. Intra-graft APCs play major role in recruiting alloreactive T cells to ischemic heart allografts. OVA 
heart donors were depleted of APCs by I.P. administration of liposomal clodronate on day −8, −5 and −1 prior 
to transplantation. Control and ischemic hearts from clodronate treated-OVA donors were transplanted in to 
OTII recipients and grafts were harvested at day 6 post-transplant. (A) Histology of APC-depleted heart grafts 
showed mild inflammatory cell infiltrates, clear patent vasculature, with similar pattern between control and 
ischemic grafts. Infiltration of CD4+ and CD8+ T cells were similar between control and ischemic grafts. (Scale 
bar 100 μm for H&E, CD4 and CD8 stain. Inset scale bar 30 μm). (B) APC depleted control and ischemic heart 
grafts showed minimal infiltration with IFNγ producing CD8+ T cells, similar in both groups (0.09 ± 0.03% vs. 
0.12 ± 0.02%, p = 0.46, n = 3/group); Representative flow plots, gated on CD8+ T cells.
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Figure 5. Antagonizing IL-6 markedly reduces alloreactive T cell infiltration following IRI. (A) Control 
and ischemic OVA hearts were transplanted into OTII recipients. Recipients were treated with anti-IL-6 
and heart grafts were harvested at day 6. No difference was noted in cell infiltration, CD4+ and CD8+ T cell 
infiltration between control and ischemic grafts. (Scale bar 100 μm for H&E, CD4 and CD8 stain. Inset scale 
bar 30 μm). (B) Absolute number of CD4+ and CD8+ T cell by flow cytometry analysis were similar in both 
groups (15.4 × 104 ± 1.4 × 104 vs. 18.5 × 104 ± 0.1 × 104, p = 0.1 for CD4+ T cells and 1.1 × 104 ± 0.1 × 104 
vs. 1.4 × 104 ± 0.1 × 104, p = 0.29 for CD8+ T cells, respectively, n = 3/group). (C) Minimal CD8+ IFNγ+ T 
cell infiltration was observed and no statistical difference was seen between ischemic and control allografts 
(0.48 ± 0.05% vs. 1.04 ± 0.2%, p = 0.05, n = 3/group). Representative flow plots, gated on CD8+ T cells. (D) 
Marked reduction in graft infiltration by CD8+ IFNγ+ T cells seen following anti-IL-6, with greater effect 
in ischemic organs. (Fold reduction in CD8+ IFNγ+: control vs. ischemia 49.04 ± 0.52 vs. 106.74 ± 2.97, 
***p < 0.001). (E) Significantly higher percentage of CD4+ Foxp3+ T cells was seen in anti-IL-6 treated 
ischemic graft compared to untreated ischemic graft (5.61 ± 0.67% vs. 2.66 ± 0.81%, *p < 0.05, n = 3/group). 
(F) Significantly lower percentage of CD4+ IL17+ T cell was seen in anti-IL-6 treated ischemic graft compared 
to untreated ischemic graft (0.33 ± 0.07% vs. 0.88 ± 0.12%, *p < 0.05, n = 3/group). (G) Significantly lower 
percentage of CD4+ IFNγ+ T cell was seen in anti-IL-6 treated ischemic graft compared to untreated ischemic 
graft (0.04 ± 0.02% vs. 5.13 ± 1.21%, *p < 0.05, n = 3/group).
www.nature.com/scientificreports/
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untreated ischemic controls: 18.5 × 104 ± 0.1 × 104 vs. 27.2 × 104 ± 2.6 × 104, *p < 0.05 for CD4+ T cells and 
1.41 × 104 ± 0.1 × 104 vs. 3.4 × 104 ± 0.2 × 104, ***p < 0.001 for CD8+ T cells, respectively, n = 3/group) (Fig. 5B: 
ischemia + anti-IL-6 and Fig. 2C: ischemia).
Anti-IL-6 led to a decrease CD8+ IFNγ+ T cell infiltration in both groups, resulting in similar frequencies in 
treated control and ischemic allografts (0.48 ± 0.05% vs.1.04 ± 0.2%, p = 0.05, respectively, n = 3/group) (Fig. 5C). 
To specifically assess the effect of anti-IL-6 on IRI-induced CD8+ IFNγ+ T cell infiltration, we compared treated 
versus untreated grafts in both control and ischemic groups. There was a notable reduction in frequency of CD8+ 
IFNγ+ T cells in both groups following anti-IL-6, but the effect size was markedly greater in ischemic grafts 
(49.04 ± 0.52 vs. 106.74 ± 2.97 fold reduction in CD8+ IFNγ+ infiltration, control vs. ischemia, ***p < 0.001, 
respectively, n = 3/group) (Fig. 5D). These data indicate that IL-6 blockade overcame the immune stimulating 
effect of IRI and prevented IRI-induced allograft infiltration by CD8+ IFNγ+ T cells.
As IL-6 is intimately involved in CD4+ T cell differentiation, we also examined the effect of anti-IL-6 on other 
T cell populations. OVA hearts were harvested and stored for 8 hours in ischemic conditions. OT II recipient mice 
were treated with anti-IL-6 versus control. On Day 6 post-transplant, heart grafts were harvested and analyzed 
by flow cytometry. Anti-IL-6 led to a significant increase in the frequency of allograft infiltrating Tregs in treated 
ischemic grafts as compared to untreated ischemic controls (5.61 ± 0.67% vs. 2.66 ± 0.81%, *p < 0.05, n = 3/
group) (Fig. 5E). Furthermore, treatment with anti-IL-6 led to a significantly lower percentage of CD4+ IL17+ T 
cells (0.33 ± 0.07% vs. 0.88 ± 0.12%, *p < 0.05, n = 3/group) (Fig. 5F) and CD4+ IFNγ+ T cells (0.04 ± 0.02% vs. 
5.13 ± 1.21%, *p < 0.05, n = 3/group) (Fig. 5G) in ischemic hearts.
Anti-IL-6 synergizes with CTLA4Ig even under severe IRI conditions. We next moved to a more 
clinically applicable treatment model comprising transplantation across full MHC mismatch (BALB/c hearts into 
C57BL/6 recipients), and more severe IRI conditions. This experimental design is more consistent with real-world 
clinical scenarios. Prior to transplantation, BALB/c heart grafts were stored for 16 hours (severely ischemic) ver-
sus transplanted within 30 minutes (control). To assess the efficacy of IL-6 blockade in this model, recipient mice 
were treated with anti-IL-6 (0.1 mg by intraperitoneal injection on days 0 to 3 and on every other day until Day13) 
and observed for heart graft survival. In this full MHC mismatch model, anti-IL-6 therapy alone failed to prolong 
heart graft survival in either control or severely ischemic hearts (MST: untreated control vs. anti-IL-6 treated 
control: 7 vs. 7 days, p = 0.12, untreated ischemia vs. anti-IL-6 treated ischemia: 7 vs. 7 days, p = 0.47, respectively, 
n = 3–6/group) (unchanged from untreated survival, see Fig. 1A).
We next assessed if T cell costimulation blockade alone could overcome the immune-activating effect of severe 
IRI. Allograft recipients were treated with a single dose of CTLA4Ig on day 2 after transplantation (250 μg IP: 
sCTLA4Ig). Following sCTLA4Ig, severely ischemic allografts had significantly accelerated allograft rejection 
compared to sCTLA4Ig-treated non-ischemic control (MST: 33 vs. 41 days, *p < 0.05, respectively, n = 5–10/
group) (Fig. 6A).
To directly target the effect of severe ischemia, recipients were treated with anti-IL-6 and sCTLA4Ig, and 
observed for heart graft survival. Surprisingly, both control and severely ischemic allografts treated with sCT-
LA4Ig and anti-IL-6 had long-term graft survival (MST: > 100 vs. > 100 days, respectively, n = 3/group) (Fig. 6A). 
Grafts were harvested at day 100 and assessed for evidence of chronic allograft rejection. Following treatment 
with both agents, histological analysis of severely ischemic grafts demonstrated similar lymphocyte infiltration 
and vasculopathy compared to control non-ischemic grafts (Fig. 6B), indicating that anti-IL-6 synergized with 
sCTLA4Ig and overcame the effect of severe ischemia on alloimmune activation to produce long term graft 
survival.
Discussion
Early intra-organ inflammation plays a pivotal role in augmenting alloimmunity32–34. IRI is an inevitable conse-
quence of transplantation and numerous studies have shown that IRI plays a central pathogenic role in initiating 
inflammatory responses and is a major determinant of graft survival2,35,36. One of the key unmet needs in the 
field of transplantation is to better understand the mechanisms involved, and devise targeted therapies to oppose 
this effect. Strategies to reduce the long-term impact of IRI are of greater clinical significance given the increas-
ing reliance on organs from older donors or those with comorbid disease, which are more susceptible to these 
injuries11–13.
IRI leads to intra-graft inflammation and innate immune activation through multiple pathways. An exagger-
ated reperfusion response is seen following partial liver transplantation, with enhanced macrophage infiltration 
and upregulation of pro-inflammatory cytokines, leading to poorer outcomes37. Following ischemia, antibody 
binding to Fc receptors expressed on innate immune cells is increased, leading to accelerated transplant vascu-
lopathy, irrespective of antibody specificity38. In lung transplantation, IRI promotes graft-infiltrating neutrophils 
which interact with graft-resident DCs, resulting in increased MHC Class II expression, IL-12 production and 
expansion of IFNγ producing CD4+ and CD8+ T cells39. Most recently, several lines of evidence suggest that IRI 
leads to complement activation via the mannose-binding lectin pathway40,41. Indeed, blockade of complement 
activation using a C1 inhibitor prevented IRI-induced accelerated allograft rejection in a murine cardiac trans-
plant model40,41.
Although the cellular mechanisms involved in alloimmune activation following IRI have been investigated 
polyclonally, alloantigen specific models allow a more in-depth examination of increased cellular immunity after 
IRI42–45. Using an antigen-specific model, we have performed a detailed analysis of the increased cellular immu-
nity following IRI. Data from transplantation of OVA donor hearts into OTI or OTII recipients reveal the critical 
importance of CD4+ T cells in promoting the accumulation of intra-graft CD8+ IFNγ producing cells. CD4+ 
T cell depletion markedly reduced the number of IFNγ producing CD8+ T cells within the ischemic allograft 
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following IRI. This finding is in keeping with prior studies demonstrating that in the absence of CD4+ T cells, 
CD8+ T cells alone could not mediate cardiac allograft rejection46.
Prior work has demonstrated the presence of a population of endogenous memory CD8+ T cells in naïve mice, 
which were observed infiltrating the graft within 48 hours of reperfusion and cause accelerated rejection following 
prolonged cold ischemia42,47. These early-infiltrating endogenous CD8+ T cells show little dependence on CD4+ T 
cell help, and in contrast to our model, CD4+ T cell depletion led to only a modest increase in allograft survival42. 
This difference suggests that these are two different populations; in contrast to endogenous memory CD8+ T cells, 
CD8+ graft infiltrating T cells observed on day 6 may be primary donor-reactive CD8+ T cells, which require 
CD4+ T cell help to develop into effector T cells. Interestingly, in both models, allograft infiltrating CD8+ IFNγ+ T 
cells induce rejection that is resistant to CTLA4Ig. Our studies were focused primarily on the allospecific response 
on day 6 post-transplant, and we did not specifically assess the role of endogenous memory CD8+ T cells in this 
model. However, our antigen specific mouse model may be unsuitable to assess cell populations like endogenous 
CD8+ memory T cells, as the impact of such cells may be inherently altered, or possibly masked, in the face of a 
substantial antigen-specific immune response. The relationship between IRI-induced endogenous memory CD8+ 
T cell infiltration and the subsequent CD4+ alloantigen specific response, both of which result in graft infiltration 
with IFNγ-producing T cells and CTLA4Ig resistant rejection, will be an important future topic for investigation.
Following ischemia, a marked increase in the level of intra-graft IL-6 was observed in the early post-transplant 
period, prior to the appearance of significant lymphocytic infiltration. On staining, CD4+ and CD8+ were not 
seen at 1 day post-transplant, suggesting APC, including allograft resident DCs, as a potential source of IL-6. 
DCs are highly specialized to absorb oxidative stress signals and increase alloimmune activation via multiple 
routes including enhanced expression of MHC class II and positive costimulatory molecules, and the secretion 
of inflammatory cytokines19. Our group has previously shown that ischemic dendritic cells increase IL-6 produc-
tion via activation of autophagy pathways48 and ischemic allografts from mice lacking autophagy-related gene-5 
in DCs had a marked reduction in IL-6 expression48. Furthermore, in vitro, IL-6 production by ischemic DCs 
leads to increased proliferation and pro-inflammatory cytokine production by allospecific CD4+ T cells16,18. In 
our current study, depletion of APC, of which allograft resident DCs are a significant population29, led to a nota-
ble suppression of the early augmentation in intra-graft IL-6, again indicating that APCs are amongst the main 
producers of IL-6 within the organ. Depletion was also associated with a marked reduction in alloreactive T cell 
recruitment and subsequent graft rejection.
Despite elevated levels of IL-6, the predominant intra-graft T cell population following IRI was CD8+ IFNγ+ T 
cells. IL-6 is classically described to promote Th17 differentiation and oppose Th1 differentiation via upregulation 
Figure 6. Anti-IL-6 synergizes with CTLA4Ig to improve graft outcomes, even under severe IRI conditions. 
BALB/c hearts were harvested and transplanted into full MHC mismatched C57BL/6 recipients within 
30 minutes (control) or after 16 hours (severely ischemic). All recipients were treated with single dose of 
CTLA4Ig on day 2 (sCTLA4Ig). Anti-IL-6 was given as described, until day 13. (A) Despite treatment with 
sCTLA4Ig, severely ischemic grafts underwent accelerated rejection compared to control. Addition of anti-IL-6 
to sCTLA4Ig treatment overcame the effect of severe ischemia, and both control and severely ischemic grafts 
survived for more than 100 days. (B) Histology at 100 days post-transplant of control and severely ischemic 
BALB/c heart grafts into C57BL/6 recipients and treated with sCTLA4Ig and anti-IL-6. Both control and 
severely ischemic grafts showed only minimal lymphocyte infiltration and little vasculopathy. (Scale bar 
100 μm).
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of SOCS1, which inhibits IFNγ signaling during T cell activation49,50. However, IL-6 is a pleiotropic cytokine and 
under certain conditions, IL-6 may augment established Th1 responses, including Th1 mediated colitis and Th1 
and Th17 immune reactivity in experimental autoimmune encephalitis51–53.
While the effect of IL-6 on Th differentiation could be model dependent, graft derived IL-6 has been pre-
viously described to be a potent driver of acute allograft rejection. IL-6−/− cardiac allografts have significantly 
prolonged survival when transplanted into WT mice. The absence or blockade of IL-6 was associated with a sig-
nificant reduction in chronic rejection and a decreased CD8+ IFNγ+ allospecific response, a similar effect to that 
observed response in our model following IRI20,21.
Migration of CD8+ T cells to the allograft is driven by antigen presentation by graft resident APCs or endothe-
lial cells54. Elevated IL-6 levels following IRI could promote this process by augmenting the capacity of APCs to 
present antigen by mechanisms such as upregulating MHC class II and costimulatory molecules, further aug-
menting innate immune responses, and dampening the suppressive activities of Tregs18,55,56. Tregs have been 
shown to preferentially aggregate around DCs and inhibit their maturation55. However, donor-derived IL-6 is 
known to decrease intra-graft Treg numbers57 and in our model, IRI led to a reduction in allograft infiltration by 
regulatory T cells. This could also have led to enhanced DC activation and antigen presentation, promoting T cell 
infiltration.
In addition, IL-6 promotes retention of infiltrating inflammatory cells, through increased levels of CCL4, 
CCL5, RANTES and IP1058, and enhances pro-inflammatory T cell differentiation21,53,59,60. Indeed, in this model, 
blockade of IL-6 led to significantly decreased allograft infiltration with CD4+ and CD8+ T cells, with reductions 
in pro-inflammatory CD4+ IL17+ and CD4+ IFNγ+ T cells, while CD4+ Foxp3+ T cells were increased compared 
to untreated ischemic controls. These changes emphasize the effect of IL-6 in driving a pro-inflammatory T cell 
response to IRI and demonstrate the efficacy of IL-6 blockade in abrogating this response.
IL-6 also promotes endothelial cell ICAM-1 expression and chemokine production, promoting leukocyte 
recruitment to sites of inflammation61. Endothelial cells do not express the IL-6 receptor but do express gp130 and 
can respond to IL-6 trans-signaling, i.e. signaling mediated by IL-6/soluble IL-6 receptor (sIL6R) complex; lead-
ing to upregulation of ICAM-161–63. Increased sIL6R levels can occur via differential mRNA splicing or cellular 
shedding, and is observed in several inflammatory conditions64,65. Whether increased sIL6R is present following 
IRI and could be a potential mechanism of endothelial cell activation and T cell recruitment to the ischemic allo-
graft is an interesting question, worthy of future study.
Anti-IL-6 therapy has been proven to be clinically efficacious in treating rheumatoid arthritis and has been 
studied for treatment of graft versus host disease, among other applications66–68. CTLA4Ig has emerged as a prom-
ising therapeutic agent in transplantation, with a better safety profile than calcineurin inhibitors69–71. However, 
CTLA4Ig treatment has been complicated by an increased rate of early acute rejection episodes69,71 and increased 
alloimmune activation of ischemic organs could increase the risk of rejection in CTLA4Ig treated patients. While 
we have previously shown the utility of anti-IL-6 in a class II mismatch model, here, we used a more clinically rel-
evant, full MHC mismatch model of prolonged ischemia, where we investigated the synergistic effects of anti-IL-6 
with CTLA4Ig72. Our data indicate a significant decrease in heart graft survival following severe IRI in sCTLA4Ig 
treated recipients, and adding anti-IL-6 abrogates this effect, by alleviating inflammation, decreasing immune 
cell trafficking to the ischemic organ and decreasing vascular injury; resulting in similar graft survival as control 
non-ischemic grafts.
In summary, our current study indicates that CD4+ alloreactive T cells play a critical role in augmenting 
alloimmune responses following IRI. Our data suggests a model whereby IRI leads to increased IL-6 production 
by APC, allospecific CD4+ infiltration, leading to graft infiltration by CD8+ IFNγ+ T cells, resulting in enhanced 
allograft injury and poorer long-term graft outcomes. IL-6 blockade abrogates IRI-augmented alloimmunity and 
combination therapy with CTLA4Ig and anti-IL-6 could be a promising therapeutic strategy for patients who 
receive highly ischemic organs.
Materials and Methods
Mice. All animal experiments and methods were performed in accordance with the relevant guidelines and 
regulations approved by the Institutional Animal Care and Use Committee of Brigham and Women’s Hospital, 
Harvard Medical University, Boston, MA (protocol number: 2016N000167/04977).
C57BL/6, BALB/c, C57BL/6-Tg (TcraTcrb)1100Mjb/ (OTI), C57BL/6-Tg(TcraTcrb)425Cbn (OTII), and 
C57BL/6-Tg(CAG-OVA)916Jen/J mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and 
used at 6–10 weeks of age. OTI and OTII mice are TCR transgenic mice specific to OVA peptide, which recognize 
either OVA257–264 or OVA 323–339 in context of MHC class I or II, respectively.
Heterotopic cardiac transplantation. Heterotopic intra-abdominal cardiac transplantation was per-
formed using microsurgical techniques as described by Corry et al.73. For most experiments, donor hearts were 
harvested, and kept at 4 degrees Celsius in University of Washington (UW) solution for 8 hours prior to trans-
plantation for ischemic conditions, whereas control group were transplanted within 30 minutes after harvest. For 
severely ischemic conditions (Fig. 6), hearts were stored in the above conditions for 16 hours prior to transplan-
tation. Graft heartbeat was evaluated daily by palpation. Rejection was determined as very weak beating in OVA/
OTII heart transplant model or complete cessation of cardiac contractility.
In vivo treatment protocols. To deplete CD4+ T cells, recipient mice were treated intravenously with 1 mg 
of anti-CD4 antibody (clone GK1.5; Bio X Cell, West Lebanon, NH) on days −3, −2 and −1 before transplan-
tation. CD4+ T cell depletion (≥98%) was confirmed in peripheral blood by flow cytometry. To deplete APCs, 
donor mice were injected with 0.5 mg liposomal clodronate (Encapsula NanoSciences, Nashville, TN) intraperi-
toneally on days −8, −5 and −1 before transplant as previously described29. For systemic IL-6 blockade, 0.1 mg 
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anti-mouse IL-6 antibody (clone cMR16–1; Courtesy of Genentech) was injected intraperitoneally into allograft 
recipients on days 0 to 3 and then on alternate days until day 13. A single dose of CTLA4Ig 250 microgram was 
injected intraperitoneally on day two following transplantation.
Lymphocyte extraction from transplanted heart grafts. Heart grafts were procured and flushed with 
PBS to remove any remaining clot. They were then minced in RPMI-1640 medium containing % 0.1 collagenase 
and incubated for one hour at 37 °C with 5% CO2 followed by addition of 0.1 M EDTA in PBS. After 5 minutes 
more incubation at 37 °C, 5 mM EDTA in PBS with 1% of FBS buffer was added. Cells were then filtered through 
70 um strainer, counted and stained for flow cytometry.
Flow cytometry. Flow cytometric analysis of graft infiltrating cells, draining lymph node (DLN) and spleen 
was performed and each leukocyte population was quantified. For intracellular cytokine staining, cells were stim-
ulated ex-vivo with PMA (50 ng/ml) and Ionomycin (500 ng/ml) in combination with GolgiStop for 4 hours, then 
permeabilized and stained with fluorochrome conjugated antibodies against IFNγ and IL-17. All antibodies were 
purchased from BD (Becton Dickinson Franklin Lakes, NJ). Cells were run on FACSCanto II (BD Biosciences, 
Franklin Lakes, NJ) instrument. Data were analyzed using FlowJo software.
ELISPOT assay. To assess production of murine IFNγ, ELISPOT assay was performed according to the man-
ufacturer’s instructions (BD Biosciences). Briefly, immunospot plates (Millipore) were coated with IFNγ primary 
antibody overnight. Donor splenocytes were harvested, processed and irradiated at 3000 Rads and then plated 
with recipients’ whole splenocytes in a 1:1 ratio and incubated in 37  °C for 24 hours. Cells were then washed out 
and detection antibody was added and incubated overnight. After development with the chromogen, the total 
number of spots per well were quantified using an ImmunoSpot Analyzer (Cellular Technology, Cleveland, OH, 
USA).
Immunohistochemistry. Heart grafts harvested at certain time points post-transplant were fixed in forma-
lin and embedded to paraffin block. Samples were then cut into 5 micron thick and stained with Hematoxylin and 
Eosin stain (H&E), CD4 and CD8. Anti-CD4 and CD8 antibodies were purchased from BD Biosciences.
Quantitative RT-PCR. Harvested cardiac grafts were flash frozen in liquid nitrogen and used for RNA 
extraction by SYBR Green-based detection. Tissues were homogenized and sonicated, and RNA was isolated 
using RNeasy mini kit (Qiagen, Valencia, CA). Harvested RNA was subsequently measured and used to prepare 
cDNA using iScript cDNA synthesis kit (Bio-Rad laboratories, Inc., Hercules, CA). Quantitative PCR was then 
performed for IL-6 genes. The primer for IL-6 is; the forward 5′-CCGGAGAGGAGACTTCACAG-3′ and the 
reverse 5′-GGAAATTGGGGTAGGAAGGA-3′. Expression was assessed as compared to GAPDH expression. 
Relative gene expression was calculated using the 2ΔΔCT method.
Statistics. Kaplan-Meier survival graphs were constructed and log rank comparison of the groups was 
used to calculate p-values for survival comparisons between various groups. Data analysis was performed using 
GraphPad Prism (GraphPad Software, Inc., San Diego, CA). Differences between groups for cellular infiltration, 
luminex and ELISPOT numbers were evaluated by student’s t-test to determine significance. *p < 0.05 was con-
sidered a significant difference.
Data Availability. All data generated or analyzed during this study are available from the corresponding 
author on reasonable request.
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